Mol Ther 2021 Apr 5. Epub 2021 Apr 5.
Department of Infectious Diseases/Virology, Medical Faculty, University of Heidelberg, Heidelberg, Germany; BioQuant, University of Heidelberg, Germany; German Center for Infection Research (DZIF) and German Center for Cardiovascular Research (DZHK), partner site Heidelberg, Germany. Electronic address:
Parvoviruses and especially the Adeno-associated virus (AAV) species provide an exciting and versatile platform for the rational design or molecular evolution of human gene therapy vectors, documented by literature from over half a century, hundreds of clinical trials and the recent commercialization of multiple AAV gene therapeutics. For the last three decades, the power of these vectors has been further potentiated through various types of hybrid vectors created by intra- or inter-genus juxtaposition of viral DNA and protein cis elements, or by synergistic complementation of parvoviral features with those of heterologous, prokaryotic or eukaryotic viruses. Here, we provide an overview of the history and promise of this rapidly expanding field of hybrid parvoviral gene therapy vectors, starting with early generations of chimeric particles composed of a recombinant AAV genome encapsidated in shells of synthetic AAVs, or of adeno-, herpes-, baculo- or protoparvoviruses. Read More